Research and Markets: Refractory Acute Myeloid Leukemia - Pipeline Review, H1 2015

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/286sl9/refractory_acute) has announced the addition of the "Refractory Acute Myeloid Leukemia - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Refractory Acute Myeloid Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Acute Myeloid Leukemia and special features on late-stage and discontinued projects.

This report features investigational drugs from across the globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles/records featured in the report undergo periodic update following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Reasons to buy

The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Mentioned

Partial list of the 50 companies featured in this comprehensive report:

  • AbbVie
  • Boehringer Ingelheim
  • Calithera Biosciences
  • Daiichi Sankyo Company
  • Eisai Co.
  • F. Hoffmann-La Roche
  • Fujifilm Corporation
  • GlaxoSmithKline
  • Igenica Biotherapeutics
  • Incyte Corporation
  • Jiangsu Hansoh Pharmaceutical
  • JW Pharmaceutical Corporation
  • Karyopharm Therapeutics
  • Kyowa Hakko Kirin
  • Les Laboratoires Servier
  • MacroGenics
  • Merck & Co.
  • Novartis
  • Otsuka Holdings
  • Oxford BioTherapeutics
  • Pharma Mar
  • Pharmacyclics
  • Seattle Genetics
  • SpectraMab
  • TaiGen Biotechnology
  • Verastem

For more information visit http://www.researchandmarkets.com/research/286sl9/refractory_acute

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology